Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights

About this update from Zhejiang Medicine Co., Ltd. Class A

Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Zhejiang Medicine Co., Ltd. Class A